Source:http://linkedlifedata.com/resource/pubmed/id/20692447
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2010-8-9
|
| pubmed:abstractText |
T cell-mediated acute rejection (ATCMR) in renal transplant patients can have an antibody-mediated component. The aim of this study was to evaluate the incidence of renal biopsies showing ATCMR with C4d immunoreactivity and the correlation between C4d-positive ATCMRs and graft outcomes. We studied 216 renal transplant patients receiving cyclosporine-based immunosuppression (mean follow-up = 203.5 +/- 42.5 months). Of these, 79 experienced biopsy-proven ATCMR (group 1), whereas 137 did not show clinical or laboratory evidence of ATCMR (group 2). Mean serum creatinine levels were evaluated at 6 months, as well as 2 and 5 years after transplantation. The number of graft losses due to interstitial fibrosis and tubular atrophy (IF/TA) was greater in group 1 than in group 2 (P < .001 and P < .02, respectively), while graft survival was lower (P < .03). Staining with anti-C4d antibody was performed in 61/77 type I ATCMR biopsies: seven cases showed diffuse C4d positivity with CD68(+) monocytes in peritubular capillaries observed in all cases. Three cases showed focal C4d positivity. Two ATCMRs were steroid, resistant. Graft loss due to IF/TA occurred in 4/7 patients (57.1%) who had previously experienced ATCMRs with diffuse C4d positivity; whereas it occurred in 5/51 patients (9.8%) with previous C4d negative ATCMRs (P < .001). Patients with focal C4d positivity did not undergo graft loss due to IF/TA. In conclusion, at our center the diffuse C4d positivity that occurred in 11.4% of type I ATCMRs was associated with a poor prognosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1873-2623
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2010 Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
42
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2214-7
|
| pubmed:meshHeading |
pubmed-meshheading:20692447-Adult,
pubmed-meshheading:20692447-Biopsy,
pubmed-meshheading:20692447-Complement C4b,
pubmed-meshheading:20692447-Creatinine,
pubmed-meshheading:20692447-Female,
pubmed-meshheading:20692447-Follow-Up Studies,
pubmed-meshheading:20692447-Graft Rejection,
pubmed-meshheading:20692447-Histocompatibility Testing,
pubmed-meshheading:20692447-Humans,
pubmed-meshheading:20692447-Incidence,
pubmed-meshheading:20692447-Kidney Transplantation,
pubmed-meshheading:20692447-Male,
pubmed-meshheading:20692447-Middle Aged,
pubmed-meshheading:20692447-Peptide Fragments,
pubmed-meshheading:20692447-Retrospective Studies,
pubmed-meshheading:20692447-Survival Rate,
pubmed-meshheading:20692447-T-Lymphocytes,
pubmed-meshheading:20692447-Treatment Outcome
|
| pubmed:articleTitle |
C4d-positive renal allograft rejection biopsies in cyclosporine-treated patients: single-center incidence and outcome.
|
| pubmed:affiliation |
Department of Diagnostic Medical Sciences, Section of Special Pathology, Unit of Kidney and Pancreas Transplantation, University of Padua, Medical School, Padua, Italy. marialuisa.valente@unipd.it
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|